Clinical practice guidelines and conflict of interest
- PMID: 16301688
- PMCID: PMC1283484
- DOI: 10.1503/cmaj.051423
Clinical practice guidelines and conflict of interest
Erratum in
- CMAJ. 2006 Jan 3;174(1):67
Comment in
-
The Canadian Diabetes Association guidelines: putting the evidence first.CMAJ. 2006 Jan 31;174(3):333-4. doi: 10.1503/cmaj.051556. CMAJ. 2006. PMID: 16446474 Free PMC article. No abstract available.
-
Not all guidelines are created equal.CMAJ. 2006 Mar 14;174(6):814-5; discussion 815. doi: 10.1503/cmaj.1060008. CMAJ. 2006. PMID: 16534092 Free PMC article. No abstract available.
-
Not all guidelines are created equal.CMAJ. 2006 Mar 14;174(6):814; discussion 815. doi: 10.1503/cmaj.1050268. CMAJ. 2006. PMID: 16534093 Free PMC article. No abstract available.
-
Evidence and advocacy: are all things considered?CMAJ. 2006 Jun 20;174(13):1856. doi: 10.1503/cmaj.060231. CMAJ. 2006. PMID: 16785461 Free PMC article. No abstract available.
References
-
- Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2003 Clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2003;27(suppl 2):S1-S152. Available: www.diabetes.ca/cpg2003/downloads/cpgcomplete.pdf (accessed 2005 Oct 31). - PubMed
-
- Canadian Coordinating Office for Health Technology Assessment. CEDAC final recommendation on reconsideration and reasons for recommendation. Insulin glargine (Lantus® — Aventis Phrama Inc.). 2005. Available: www.ccohta.ca/CDR/cdr_pdf/cdr_submissions/Complete/cdr_complete_Lantus_2... (accessed 2005 Oct 31).
-
- Taylor R, Giles J. Cash interests taint drug advice. Nature 2005;437:1070-1. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources